Literature DB >> 32409967

Risk Factors and Prognostic Impact of Mediastinal Lymph Node Metastases in Patients with Esophagogastric Junction Cancer.

Osamu Shiraishi1, Takushi Yasuda2, Hiroaki Kato2, Mitsuru Iwama2, Yoko Hiraki2, Atsushi Yasuda2, Masayuki Shinkai2, Yutaka Kimura2, Motohiro Imano2.   

Abstract

PURPOSE: We retrospectively investigated the risk factors for mediastinal lymph node (MLN) metastasis in esophagogastric junction (EGJ) cancer with an epicenter within 2 cm above and below the anatomical cardia, including both adenocarcinoma (AC) and squamous cell carcinoma (SCC).
METHODS: Fifty patients who underwent initial surgery for EGJ cancer from January 2002 to December 2013 were included in this study. We defined metastatic lymph nodes as pathological metastases in resected specimens and recurrence within 2 years postoperatively.
RESULTS: Thirty-four patients had AC and 16 had SCC; 24 patients underwent transhiatal resection and 26 underwent transthoracic resection. MLN metastasis was observed in 13 patients (26%) regardless of the histological type, 9 of whom had metastasis in the upper and middle mediastinum. Metastasis occurred when the esophageal invasion length (EIL) exceeded 20 mm. In addition, 10/13 patients had stage pN2-3 cancer. Multivariable analysis identified EIL ≥ 20 mm and stage pN2-3 as significant risk factors for MLN metastasis. The 5-year overall survival was 38% and 65% in the MLN-positive and -negative groups, respectively (p = 0.12). Multivariable Cox regression analysis showed that only stage pN2-3, and not the presence of MLN metastasis, was a significantly poor prognostic factor.
CONCLUSION: MLN metastasis in EGJ cancer may have a close association with the EIL of the tumor, but the presence of MLN metastasis itself was not a poor prognostic factor. The significance and indications for MLN dissection should be clarified in prospective clinical trials.

Entities:  

Mesh:

Year:  2020        PMID: 32409967     DOI: 10.1245/s10434-020-08579-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  24 in total

1.  7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction.

Authors:  Thomas W Rice; Eugene H Blackstone; Valerie W Rusch
Journal:  Ann Surg Oncol       Date:  2010-07       Impact factor: 5.344

2.  Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial.

Authors:  Mitsuru Sasako; Takeshi Sano; Seiichiro Yamamoto; Motonori Sairenji; Kuniyoshi Arai; Taira Kinoshita; Atsushi Nashimoto; Masahiro Hiratsuka
Journal:  Lancet Oncol       Date:  2006-08       Impact factor: 41.316

Review 3.  Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment.

Authors:  Steven R DeMeester
Journal:  Ann Surg Oncol       Date:  2006-01-01       Impact factor: 5.344

4.  Classification of adenocarcinoma of the oesophagogastric junction.

Authors:  J R Siewert; H J Stein
Journal:  Br J Surg       Date:  1998-11       Impact factor: 6.939

5.  Cancer of the gastric cardia is rising in incidence in an Asian population and is associated with adverse outcome.

Authors:  Chris Deans; Matthew S W Yeo; Mu Yar Soe; Asim Shabbir; T K Ti; Jimmy B Y So
Journal:  World J Surg       Date:  2011-03       Impact factor: 3.352

6.  Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma.

Authors:  Hiroharu Yamashita; Yasuyuki Seto; Takeshi Sano; Hiroyasu Makuuchi; Nobutoshi Ando; Mitsuru Sasako
Journal:  Gastric Cancer       Date:  2016-10-28       Impact factor: 7.370

Review 7.  Western strategy for EGJ carcinoma.

Authors:  Simone Giacopuzzi; Maria Bencivenga; Jacopo Weindelmayer; Giuseppe Verlato; Giovanni de Manzoni
Journal:  Gastric Cancer       Date:  2016-12-30       Impact factor: 7.370

8.  Thoracoabdominal versus transhiatal surgical approaches for adenocarcinoma of the esophagogastric junction-a systematic review and meta-analysis.

Authors:  Patrick Heger; Susanne Blank; Käthe Gooßen; Henrik Nienhüser; Markus K Diener; Alexis Ulrich; André L Mihaljevic; Thomas Schmidt
Journal:  Langenbecks Arch Surg       Date:  2019-01-03       Impact factor: 3.445

9.  Tumors of the esophagogastric junction. Long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification.

Authors:  W H Steup; P De Leyn; G Deneffe; D Van Raemdonck; W Coosemans; T Lerut
Journal:  J Thorac Cardiovasc Surg       Date:  1996-01       Impact factor: 5.209

10.  Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial.

Authors:  Jikke M T Omloo; Sjoerd M Lagarde; Jan B F Hulscher; Johannes B Reitsma; Paul Fockens; Herman van Dekken; Fiebo J W Ten Kate; Huug Obertop; Hugo W Tilanus; J Jan B van Lanschot
Journal:  Ann Surg       Date:  2007-12       Impact factor: 12.969

View more
  2 in total

1.  Letter to Editor of Annals of Surgical Oncology Concerning "Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis".

Authors:  Fabio Carboni; Mario Valle
Journal:  Ann Surg Oncol       Date:  2021-10-22       Impact factor: 5.344

2.  Association of anastomotic leakage with long-term oncologic outcomes of patients with esophagogastric junction cancer.

Authors:  Masashi Takeuchi; Hirofumi Kawakubo; Satoru Matsuda; Shuhei Mayanagi; Tomoyuki Irino; Jun Okui; Kazumasa Fukuda; Rieko Nakamura; Norihito Wada; Hiroya Takeuchi; Yuko Kitagawa
Journal:  World J Gastrointest Surg       Date:  2022-01-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.